Literature DB >> 23039992

RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Christopher A Nelson1, Julia T Warren, Michael W-H Wang, Steven L Teitelbaum, Daved H Fremont.   

Abstract

Osteoprotegerin (OPG) and receptor activator of nuclear factor κB (RANK) are members of the tumor necrosis factor receptor (TNFR) superfamily that regulate osteoclast formation and function by competing for RANK ligand (RANKL). RANKL promotes osteoclast development through RANK activation, while OPG inhibits this process by sequestering RANKL. For comparison, we solved crystal structures of RANKL with RANK and RANKL with OPG. Complementary biochemical and functional studies reveal that the monomeric cytokine-binding region of OPG binds RANKL with ∼500-fold higher affinity than RANK and inhibits RANKL-stimulated osteoclastogenesis ∼150 times more effectively, in part because the binding cleft of RANKL makes unique contacts with OPG. Several side chains as well as the C-D and D-E loops of RANKL occupy different orientations when bound to OPG versus RANK. High affinity OPG binding requires a 90s loop Phe residue that is mutated in juvenile Paget's disease. These results suggest cytokine plasticity may help to fine-tune specific tumor necrosis factor (TNF)-family cytokine/receptor pair selectivity.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23039992      PMCID: PMC3607351          DOI: 10.1016/j.str.2012.08.030

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  60 in total

1.  Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.

Authors:  A Truneh; S Sharma; C Silverman; S Khandekar; M P Reddy; K C Deen; M M McLaughlin; S M Srinivasula; G P Livi; L A Marshall; E S Alnemri; W V Williams; M L Doyle
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

2.  Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.

Authors:  J Mongkolsapaya; J M Grimes; N Chen; X N Xu; D I Stuart; E Y Jones; G R Screaton
Journal:  Nat Struct Biol       Date:  1999-11

Review 3.  Bone modeling and remodeling.

Authors:  Ego Seeman
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

Review 4.  On the TRAIL to apoptosis.

Authors:  Tudor M Baetu; John Hiscott
Journal:  Cytokine Growth Factor Rev       Date:  2002-06       Impact factor: 7.638

Review 5.  Modularity in the TNF-receptor family.

Authors:  J H Naismith; S R Sprang
Journal:  Trends Biochem Sci       Date:  1998-02       Impact factor: 13.807

6.  Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis.

Authors:  Hai Minh Ta; Giang Thi Tuyet Nguyen; Hye Mi Jin; Jongkeun Choi; Hyejin Park; Nacksung Kim; Hye-Yeon Hwang; Kyeong Kyu Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 7.  To die or not to die--the quest of the TRAIL receptors.

Authors:  M Degli-Esposti
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

8.  Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene.

Authors:  N Kim; P R Odgren; D K Kim; S C Marks; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

9.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

Authors:  A Mizuno; N Amizuka; K Irie; A Murakami; N Fujise; T Kanno; Y Sato; N Nakagawa; H Yasuda; S Mochizuki; T Gomibuchi; K Yano; N Shima; N Washida; E Tsuda; T Morinaga; K Higashio; H Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1998-06-29       Impact factor: 3.575

10.  The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor.

Authors:  B R Wong; R Josien; S Y Lee; M Vologodskaia; R M Steinman; Y Choi
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

View more
  52 in total

1.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

Review 2.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

3.  Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.

Authors:  Jerome T Higgs; John S Jarboe; Joo Hyoung Lee; Diptiman Chanda; Carnellia M Lee; Champion Deivanayagam; Selvarangan Ponnazhagan
Journal:  Mol Cancer Res       Date:  2015-01-30       Impact factor: 5.852

4.  Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.

Authors:  Matthieu C J Bosman; Carlos R Reis; Jan J Schuringa; Edo Vellenga; Wim J Quax
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

Review 5.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

6.  Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier.

Authors:  Aruna Bitra; Tzanko Doukov; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

7.  Testosterone regulates bone response to inflammation.

Authors:  J P Steffens; B S Herrera; L S Coimbra; D N Stephens; C Rossa; L C Spolidorio; A Kantarci; T E Van Dyke
Journal:  Horm Metab Res       Date:  2014-02-13       Impact factor: 2.936

Review 8.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

9.  Heparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis.

Authors:  Miaomiao Li; Shuying Yang; Ding Xu
Journal:  J Biol Chem       Date:  2016-10-03       Impact factor: 5.157

Review 10.  Adenosine and bone metabolism.

Authors:  Aránzazu Mediero; Bruce N Cronstein
Journal:  Trends Endocrinol Metab       Date:  2013-03-14       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.